In a major move, Vectura Fertin Pharma, Inc., an affiliate of Philip Morris International Inc. (PM) , announced the sale of Vectura Group Ltd. to Molex Asia Holdings Ltd. This decision comes amid ongoing criticism of PM’s ownership of the asthma inhaler manufacturer as PM attempts to transition from tobacco to a broader healthcare and wellness group. Philip Morris stated that this transaction allows Vectura to operate under Phillips Medisize, a Molex subsidiary, which is better positioned to advance its inh ...

Philip Morris International Inc. (PM) has demonstrated impressive upward momentum, consistently trading above its 200-day and 50-day simple moving averages (SMA), key indicators of price stability and long-term bullish trends.  As of Sept. 18, PM was trading at $120.96, which surpassed both its 200-day SMA of $99.21 and 50-day SMA of $117.16, highlighting a continued uptrend. Image Source: Zacks Investment ResearchSMA is a key tool in technical analysis used to assess price trends by smoothing out short-ter ...

Investors have mostly given up on this sector, but returns have been massive over the long run.It can pay to track the investing legends. Billionaire Stanley Druckenmiller put up 30% returns for 30 years when running his hedge fund, and he never had a down year for his investors. Clearly, he is one of the best investors out there, making it worthwhile to track what he is buying and selling.While you shouldn't blindly follow the investing legends, it can be a great source of inspiration for potential new sto ...

In a major move, Vectura Fertin Pharma, Inc., an affiliate of Philip Morris International Inc. (PM) , announced the sale of Vectura Group Ltd. to Molex Asia Holdings Ltd. This decision comes amid ongoing criticism of PM’s ownership of the asthma inhaler manufacturer as PM attempts to transition from tobacco to a broader healthcare and wellness group.Philip Morris stated that this transaction allows Vectura to operate under Phillips Medisize, a Molex subsidiary, which is better positioned to advance its inha ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.It also includes access to the Zacks Style Scores.What are the Zacks Style Scores?The Zacks ...

FotografiaBasica Philip Morris (NYSE:PM) is one of the largest tobacco companies in the world, with a market capitalization of almost $200 billion. The company has a dividend of more than 4% and an incredibly strong portfolio of assets. As we'll see throughout this article, Philip Morris has an impressive portfolio of assets that will support future shareholder returns. We last discussed the company just over a year ago. Since then, the company has almost doubled the performance of the S&P 500, supporte ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even ...

Shares of Philip Morris International Inc. (PM) reached a 52-week high of $127.41 on Wednesday before closing the trading session at $126.61. The company’s strategic focus on smoke-free products, driven by growing consumer health consciousness, has been a key factor in its success. Its pricing power has also bolstered performance.These factors have fueled a 21.5% rally in Philip Morris shares over the past three months, outpacing the broader industry’s growth of 20.7%. PM also surpassed the Zacks Consumer S ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Considering buying PM stock? Here’s what analysts think: Read Next: ...

Summary of Philip Morris International Inc. Conference Call Company Overview - **Company**: Philip Morris International Inc. (NYSE: PM) - **Event**: Barclays Global Consumer Staples Conference 2024 - **Date**: September 3, 2024 - **Participants**: Jacek Olczak (CEO), Gaurav Jain (Barclays) Key Points Stock Performance - PMI stock is trading at all-time highs, with a year-to-date increase of 35%, outperforming the S&P Staples Index (up 16%) and S&P/NASDAQ (up about 20%) [1][2] Growth Expectations - Discussion on whether PMI can systematically outperform the S&P 500 moving forward [2] - Historical context provided, noting that PMI previously targeted 10% to 12% EPS growth driven by emerging markets, now focusing on high profit pool markets like the U.S. and Europe, alongside New Generation Products (NGPs) [2][3] Volume and Revenue Growth - PMI has achieved volume growth despite challenges in the traditional tobacco market, with mid-single-digit revenue growth driven by a favorable volume mix and strong pricing [5][6] - The company expects to deliver 11% to 13% EPS growth without share buybacks, indicating a strong recovery compared to previous years [5] NGP Market Dynamics - NGPs, including heat-not-burn products and nicotine pouches, are seen as key drivers for future growth, with significant market potential still untapped [11][12] - The company is optimistic about the volume outlook, suggesting a shift in consumer behavior towards smoke-free alternatives [13][14] Pricing Strategy - PMI is cautious about pricing strategies, balancing market share with profitability, particularly in the combustible cigarette segment [17][20] - The company has indicated strong pricing variance, even with reduced cigarette volumes, and is focused on maximizing the value of its product offerings [18][19] IQOS Performance - There have been adjustments in IQOS guidance, but the company remains confident in its long-term growth trajectory, particularly in markets like Japan where heat-not-burn products are gaining traction [21][23] - The impact of the EU flavor ban on IQOS is acknowledged, with expectations for recovery in growth as markets adapt [27][28] ZYN Capacity Expansion - PMI is expanding ZYN production capacity, with plans for a new facility in Colorado and maximizing existing operations in Owensboro, Kentucky [30][31] - Despite recent market share losses, the company believes ZYN has been a significant growth driver for the category and anticipates regaining share as capacity constraints are addressed [32][33] Youth Access and Regulatory Compliance - PMI is actively managing youth access to its products, emphasizing responsible marketing and distribution practices [36][40] - The company is awaiting FDA decisions on regulatory submissions for ZYN and is committed to preventing unauthorized product access [41] Share Repurchase and Financial Strategy - PMI is currently above its 2x leverage target but aims to return to this level by 2026, at which point share repurchases may be considered [42][44] - The company prioritizes dividends and cash flow management, indicating a strong commitment to shareholder returns [45][46] Conclusion - PMI is navigating a transformative period with a focus on NGPs, pricing strategies, and regulatory compliance while maintaining a commitment to shareholder value through dividends and potential share repurchases in the future [48][49]